Bashar Issa
Contributor since: 2020
Myriad: Trying To Find Its Footing In An Evolving Industry
Invitae Busted Business Model Offers A Tactical Opportunity
Rethinking My Clover Health Position
agilon health: A Novel Business Model Brings Novel Risks
Owl Rock Capital: Crowded Marriage - Management's Conflict Of Interest
Humana: Time To Adopt A More Defensive Portfolio Strategy
Exela Technologies: No Way Out. Likely Going Bankrupt
UnitedHealth: This Defensive Trade Has Been Exhausted
Alignment Healthcare: This Next-Generation Medicare Startup Is Fully Valued
Clover Paid The Price Of Its Alleged Lies; Time To Move On
Bionano: Volatility And Q2 Earnings Under The Spotlight
Palantir: Falling Knife, Not A 'Buy The Dip' Opportunity
Gladstone Investment's Secret Of Success: Management Integrity
Blue Owl: Structural Risk Hiding Within Revenue Momentum
Microsoft Can Handle Slowing Economy
Amazon's High-Stakes Earnings Results
How Shanghai Police Data Leak Impacts Alibaba
FS KKR: You Don't Want To Hold This During A Recession
Barings' Recession Scenario Breakpoint: A 20% Fall In Portfolio Fair Value
Beyond Bionano's 80% Growth: Cracks In Management's Claim Of A Momentum
Imperial Metals: High Risk/Reward Copper Play
IBM: Time To Put Dividend Safety Debate To Bed
Palantir: Dead Cat Bounce
Mr. Cooper Group: Prepare For A Soft Q2
AES: A Defensive Stock For Volatile Markets
Teradyne Revenue Likely To Decline In The Coming Quarters
Cintas' Fiery Valuation Overshadows Growth Expectations
VICI Properties: The First Line Of Defense Against Volatile Markets
Good News For Medical Properties Investors
The Reason Apple And Microsoft Are Better Than Alphabet And Meta
Apple's Netflix Fate On Active iPhone Users Base
Alibaba: 3 Reasons To Sell In May And Go Away
Manulife: Fed-Resistant, Investment-Grade, 5% Yield
Fidelity: Fed-Resistant 4% Investment-Grade Dividend
Alibaba: A Rough Patch Ahead
AT&T: The Leg-Pulling Oligopoly Facade And Why I'm Buying
Palantir's Invisible Glass Ceiling
Editas: The Unforeseen Detrimental Effect Of Patent Win
The Commercial Potential Of Crispr In Light Of Patent Challenges
Intellia: One Patent Ruling Turns The Industry Upside Down